Logo image of ALGEN.PA

GENOWAY SA (ALGEN.PA) Stock Fundamental Analysis

EPA:ALGEN - Euronext Paris - Matif - FR0004053510 - Common Stock - Currency: EUR

3.46  +0.05 (+1.47%)

Fundamental Rating

6

Overall ALGEN gets a fundamental rating of 6 out of 10. We evaluated ALGEN against 72 industry peers in the Biotechnology industry. ALGEN has an excellent profitability rating, but there are some minor concerns on its financial health. ALGEN has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

ALGEN had positive earnings in the past year.
ALGEN had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: ALGEN reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: ALGEN reported negative operating cash flow in multiple years.
ALGEN.PA Yearly Net Income VS EBIT VS OCF VS FCFALGEN.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2M -2M -4M

1.2 Ratios

Looking at the Return On Assets, with a value of 3.96%, ALGEN belongs to the top of the industry, outperforming 87.50% of the companies in the same industry.
ALGEN has a better Return On Equity (7.06%) than 81.94% of its industry peers.
The Return On Invested Capital of ALGEN (5.79%) is better than 83.33% of its industry peers.
Industry RankSector Rank
ROA 3.96%
ROE 7.06%
ROIC 5.79%
ROA(3y)2.1%
ROA(5y)-0.32%
ROE(3y)3.96%
ROE(5y)-2.21%
ROIC(3y)N/A
ROIC(5y)N/A
ALGEN.PA Yearly ROA, ROE, ROICALGEN.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10 20

1.3 Margins

ALGEN's Profit Margin of 5.86% is fine compared to the rest of the industry. ALGEN outperforms 79.17% of its industry peers.
In the last couple of years the Profit Margin of ALGEN has grown nicely.
ALGEN has a better Operating Margin (8.09%) than 81.94% of its industry peers.
ALGEN's Operating Margin has improved in the last couple of years.
ALGEN has a Gross Margin of 92.34%. This is amongst the best in the industry. ALGEN outperforms 90.28% of its industry peers.
ALGEN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 8.09%
PM (TTM) 5.86%
GM 92.34%
OM growth 3YN/A
OM growth 5Y13.07%
PM growth 3YN/A
PM growth 5Y8.13%
GM growth 3Y-1.3%
GM growth 5Y1.19%
ALGEN.PA Yearly Profit, Operating, Gross MarginsALGEN.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 40 60 80

More info and screens

6

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ALGEN is destroying value.
ALGEN has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ALGEN has more shares outstanding
Compared to 1 year ago, ALGEN has an improved debt to assets ratio.
ALGEN.PA Yearly Shares OutstandingALGEN.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
ALGEN.PA Yearly Total Debt VS Total AssetsALGEN.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

ALGEN has an Altman-Z score of 2.65. This is not the best score and indicates that ALGEN is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of ALGEN (2.65) is better than 75.00% of its industry peers.
The Debt to FCF ratio of ALGEN is 1.41, which is an excellent value as it means it would take ALGEN, only 1.41 years of fcf income to pay off all of its debts.
ALGEN's Debt to FCF ratio of 1.41 is amongst the best of the industry. ALGEN outperforms 94.44% of its industry peers.
ALGEN has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
ALGEN has a better Debt to Equity ratio (0.26) than 62.50% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 1.41
Altman-Z 2.65
ROIC/WACC0.75
WACC7.73%
ALGEN.PA Yearly LT Debt VS Equity VS FCFALGEN.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M 10M 15M

2.3 Liquidity

A Current Ratio of 1.92 indicates that ALGEN should not have too much problems paying its short term obligations.
ALGEN has a Current ratio (1.92) which is in line with its industry peers.
ALGEN has a Quick Ratio of 1.81. This is a normal value and indicates that ALGEN is financially healthy and should not expect problems in meeting its short term obligations.
ALGEN's Quick ratio of 1.81 is in line compared to the rest of the industry. ALGEN outperforms 44.44% of its industry peers.
Industry RankSector Rank
Current Ratio 1.92
Quick Ratio 1.81
ALGEN.PA Yearly Current Assets VS Current LiabilitesALGEN.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for ALGEN have decreased strongly by -20.89% in the last year.
ALGEN shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 12.75% yearly.
The Revenue has grown by 15.03% in the past year. This is quite good.
Measured over the past years, ALGEN shows a quite strong growth in Revenue. The Revenue has been growing by 13.16% on average per year.
EPS 1Y (TTM)-20.89%
EPS 3YN/A
EPS 5Y12.75%
EPS Q2Q%-29.99%
Revenue 1Y (TTM)15.03%
Revenue growth 3Y22.09%
Revenue growth 5Y13.16%
Sales Q2Q%14.77%

3.2 Future

Based on estimates for the next years, ALGEN will show a very negative growth in Earnings Per Share. The EPS will decrease by -33.06% on average per year.
ALGEN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.87% yearly.
EPS Next Y-20%
EPS Next 2Y-29.29%
EPS Next 3Y-33.06%
EPS Next 5YN/A
Revenue Next Year9.95%
Revenue Next 2Y10.4%
Revenue Next 3Y12.87%
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
ALGEN.PA Yearly Revenue VS EstimatesALGEN.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M 20M 25M
ALGEN.PA Yearly EPS VS EstimatesALGEN.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.05 0.1 0.15 0.2

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 24.71, the valuation of ALGEN can be described as rather expensive.
Based on the Price/Earnings ratio, ALGEN is valued cheaper than 84.72% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 29.35. ALGEN is around the same levels.
The Price/Forward Earnings ratio is 33.59, which means the current valuation is very expensive for ALGEN.
ALGEN's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. ALGEN is cheaper than 79.17% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ALGEN to the average of the S&P500 Index (22.10), we can say ALGEN is valued expensively.
Industry RankSector Rank
PE 24.71
Fwd PE 33.59
ALGEN.PA Price Earnings VS Forward Price EarningsALGEN.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

ALGEN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ALGEN is cheaper than 94.44% of the companies in the same industry.
ALGEN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ALGEN is cheaper than 95.83% of the companies in the same industry.
Industry RankSector Rank
P/FCF 7.24
EV/EBITDA 5.67
ALGEN.PA Per share dataALGEN.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2

4.3 Compensation for Growth

The decent profitability rating of ALGEN may justify a higher PE ratio.
ALGEN's earnings are expected to decrease with -33.06% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)1.94
EPS Next 2Y-29.29%
EPS Next 3Y-33.06%

More info and screens

0

5. Dividend

5.1 Amount

ALGEN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GENOWAY SA

EPA:ALGEN (3/7/2025, 7:00:00 PM)

3.46

+0.05 (+1.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners5.68%
Inst Owner ChangeN/A
Ins Owners9.39%
Ins Owner ChangeN/A
Market Cap32.80M
Analysts86.67
Price Target6.12 (76.88%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-9.09%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)60%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-7.14%
Revenue NY rev (3m)-7.14%
Valuation
Industry RankSector Rank
PE 24.71
Fwd PE 33.59
P/S 1.53
P/FCF 7.24
P/OCF 4.75
P/B 1.84
P/tB 2.7
EV/EBITDA 5.67
EPS(TTM)0.14
EY4.05%
EPS(NY)0.1
Fwd EY2.98%
FCF(TTM)0.48
FCFY13.81%
OCF(TTM)0.73
OCFY21.06%
SpS2.26
BVpS1.88
TBVpS1.28
PEG (NY)N/A
PEG (5Y)1.94
Profitability
Industry RankSector Rank
ROA 3.96%
ROE 7.06%
ROCE 7.62%
ROIC 5.79%
ROICexc 7.37%
ROICexgc 10.74%
OM 8.09%
PM (TTM) 5.86%
GM 92.34%
FCFM 21.15%
ROA(3y)2.1%
ROA(5y)-0.32%
ROE(3y)3.96%
ROE(5y)-2.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y12.04%
ROICexc growth 3YN/A
ROICexc growth 5Y11.6%
OM growth 3YN/A
OM growth 5Y13.07%
PM growth 3YN/A
PM growth 5Y8.13%
GM growth 3Y-1.3%
GM growth 5Y1.19%
F-Score5
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 1.41
Debt/EBITDA 0.77
Cap/Depr 55.06%
Cap/Sales 11.1%
Interest Coverage 250
Cash Conversion 114.18%
Profit Quality 360.76%
Current Ratio 1.92
Quick Ratio 1.81
Altman-Z 2.65
F-Score5
WACC7.73%
ROIC/WACC0.75
Cap/Depr(3y)73.44%
Cap/Depr(5y)126.53%
Cap/Sales(3y)12.12%
Cap/Sales(5y)17.89%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.89%
EPS 3YN/A
EPS 5Y12.75%
EPS Q2Q%-29.99%
EPS Next Y-20%
EPS Next 2Y-29.29%
EPS Next 3Y-33.06%
EPS Next 5YN/A
Revenue 1Y (TTM)15.03%
Revenue growth 3Y22.09%
Revenue growth 5Y13.16%
Sales Q2Q%14.77%
Revenue Next Year9.95%
Revenue Next 2Y10.4%
Revenue Next 3Y12.87%
Revenue Next 5YN/A
EBIT growth 1Y0.64%
EBIT growth 3YN/A
EBIT growth 5Y27.95%
EBIT Next Year47.62%
EBIT Next 3Y30.81%
EBIT Next 5YN/A
FCF growth 1Y67.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.68%
OCF growth 3YN/A
OCF growth 5Y7.2%